

Application Serial No.: 10/613,262

RESTRICTION PRESENTED

The Examiner contends that the claims are directed to the following patentably distinct species of tumor antigens:

Specie I - TERT; and

Specie II - TRP-2

APPLICANTS' ELECTION

Applicants hereby elect the invention of Specie I, TERT, for prosecution at this time.

REMARKS

Claims 1-35 are now pending in the subject U.S. patent application. Claims 10-15 and 19-35 as filed have been subjected to a Restriction/Election Requirement based on a contention of a patentably distinct species. The present species election is made without traverse through the extent that it is understood that, upon the finding of a allowable species, examination will continue until all species have been examined, or a non-allowable species is found, all in accordance with the procedure set forth in Manual of Patent Examining Procedure §803.02.

Each of claims 10-15, 19-21, and 23-35 are believed to read upon the elected species, either in whole or in part.

In response to the Restriction/Election Requirement, applicants have elected TERT as a species upon which to continue the search, for prosecution at this time.

Application Serial No.: 10/613,262

Applicants hereby reserve the right to file one or more divisional patent applications directed to the unelected subject matter, as well as the right to request rehoinder of unelected subject matter as might be appropriate as prosecution continues.

CONCLUSIONS

Should there be any minor issues outstanding in this matter, the Examiner is respectfully requested to telephone the undersigned attorney. Early passage of the subject application to issue is earnestly solicited.

DEPOSIT ACCOUNT


The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account Number 50-0426.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Date: June 15, 2007

By:


Arles A. Taylor, Jr.
Registration No. 39,395

AAT/omb

Customer No: 25297

297/204 PCT/US